Clarient Buys Applied Genomics to Pave Way to EGFR Testing Market for NSCLC

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.